Plexxikon's PLX3397 selected for I-SPY 2 breast cancer trial

Daiichi Sankyo subsidiary Plexxikon's oral small molecule PLX3397 joined the ranks of Amgen's trebananib and ganitumab as well as ganetespib from Synta Pharmaceuticals in the large, multi-arm, investigator-sponsored breast cancer clinical trial known as I-SPY 2.